Fine-tuning of defensive behaviors in the dorsal periaqueductal gray by atypical neurotransmitters

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 4, 2012, Pages 357-365

  Fogaca M V ^a   Lisboa, S F ^a   Aguiar, D C ^b   Moreira, F A ^b   Gomes, F V ^a   Casarotto, P C ^a   Guimaraes F S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anandamide; Endocannabinoid; Endovanilloid; Nitric oxide; Trpv1

Indexed keywords

1H [1,2,4]OXADIAZOL[4,3 A]QUINOXALIN 1 ONE; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; ENDOCANNABINOID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GUANYLATE CYCLASE INHIBITOR; METABOTROPIC RECEPTOR; MIDAZOLAM; MUSCIMOL; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; SEROTONIN 1A AGONIST; SEROTONIN 2A AGONIST; SUBSTANCE P; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VIRODHAMINE;

ANXIETY DISORDER; AVERSIVE BEHAVIOR; DEFENSIVE BEHAVIOR; DOSE RESPONSE; ENZYME ACTIVATION; ESCAPE BEHAVIOR; IMMUNOHISTOCHEMISTRY; NERVE CELL; NEUROTRANSMISSION; NITRERGIC NERVE; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; REVIEW;

EID: 84859615874     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500029     Document Type: Review

References (89)

1. Bandler R, Shipley MT. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? Trends Neurosci 1994; 17: 379-389.
2. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995; 46: 575-605.
3. Schenberg LC, Bittencourt AS, Sudre EC, Vargas LC. Modeling panic attacks. Neurosci Biobehav Rev 2001; 25: 647-659.
4. Schenberg LC. Towards a translational model of panic attack. Psychology Neurosci 2010; 3: 9-37.
5. Nashold BS Jr, Wilson WP, Slaughter DG. Sensations evoked by stimulation in the midbrain of man. J Neurosurg 1969; 30: 14-24.
6. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B, et al. When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science 2007; 317: 1079-1083.
7. Canteras NS, Resstel LB, Bertoglio LJ, Carobrez AP, Guimaraes FS. Neuroanatomy of anxiety. Curr Top Behav Neurosci 2010; 2: 77-96.
8. Griffiths JL, Lovick TA. Co-localization of 5-HT2A-receptorand GABA-immunoreactivity in neurones in the periaq-ueductal grey matter of the rat. Neurosci Lett 2002; 326: 151-154.
9. Moraes CL, Bertoglio LJ, Carobrez AP. Interplay between glutamate and serotonin within the dorsal periaqueductal gray modulates anxiety-related behavior of rats exposed to the elevated plus-maze. Behav Brain Res 2008; 194: 181-186.
10. Brandao ML, Anseloni VZ, Pandossio JE, De Araujo JE, Castilho VM. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci Biobehav Rev 1999; 23: 863-875.
11. Lovick TA. Panic disorder - a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter? Neuroscientist 2000; 6: 48-59.
12. Tolle TR, Berthele A, Zieglgansberger W, Seeburg PH, Wisden W. The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray. J Neurosci 1993; 13: 5009-5028.
13. Bandler R, Carrive P. Integrated defence reaction elicited by excitatory amino acid microinjection in the midbrain periaqueductal grey region of the unrestrained cat. Brain Res 1988; 439: 95-106.
14. Bertoglio LJ, Zangrossi H Jr. Involvement of dorsolateral periaqueductal gray N-methyl-D-aspartic acid glutamate receptors in the regulation of risk assessment and inhibitory avoidance behaviors in the rat elevated T-maze. Behav Pharmacol 2006; 17: 589-596.
15. Guimaraes FS, Carobrez AP, De Aguiar JC, Graeff FG. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 1991; 103: 91-94.
16. Molchanov ML, Guimaraes FS. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology 2002; 160: 30-38.
17. Matheus MG, Guimaraes FS. Antagonism of non-NMDA receptors in the dorsal periaqueductal grey induces anxiolytic effect in the elevated plus maze. Psychopharmacology 1997; 132: 14-18.
18. Lima VC, Molchanov ML, Aguiar DC, Campos AC, Guimaraes FS. Modulation of defensive responses and anxiety-like behaviors by group I metabotropic glutamate receptors located in the dorsolateral periaqueductal gray. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 178-185.
19. Russo AS, Guimaraes FS, De Aguiar JC, Graeff FG. Role of benzodiazepine receptors located in the dorsal periaqueductal grey of rats in anxiety. Psychopharmacology 1993; 110: 198-202.
20. de Paula Soares V, Zangrossi H Jr. Involvement of 5-HT1A and 5-HT2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the elevated T-maze. Brain Res Bull 2004; 64: 181-188.
21. Graeff FG, Brandao ML, Audi EA, Schutz MT. Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. Behav Brain Res 1986; 22: 173-180.
22. Aguiar MS, Brandao ML. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol Behav 1996; 60: 1183-1186.
23. Netto CF, Guimaraes FS. Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray. Neuropsychopharmacology 2004; 29: 101-107.
24. Litvin Y, Pentkowski NS, Blanchard DC, Blanchard RJ. CRF type 1 receptors in the dorsal periaqueductal gray modulate anxiety-induced defensive behaviors. Horm Behav 2007; 52: 244-251.
25. Esplugues JV. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002; 135: 1079-1095.
26. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-884.
27. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
28. Guimaraes FS, Beijamini V, Moreira FA, Aguiar DC, de Lucca AC. Role of nitric oxide in brain regions related to defensive reactions. Neurosci Biobehav Rev 2005; 29: 1313-1322.
29. Moreira FA, Aguiar DC, Resstel LB, Lisboa SF, Campos AC, Gomes FV, et al. Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. J Psychopharmacol 2012.; [DOI: 10.1177/0269881111400651].
30. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992; 46: 755-784.
31. Aguiar DC, Moreira FA, Guimaraes FS. Flight reactions induced by injection of glutamate N-methyl-d-aspartate receptor agonist into the rat dorsolateral periaqueductal gray are not dependent on endogenous nitric oxide. Pharmacol Biochem Behav 2006; 83: 296-301.
32. Guimaraes FS, De Aguiar JC, Del Bel EA, Ballejo G. Anxiolytic effect of nitric oxide synthase inhibitors microinjected into the dorsal central grey. Neuroreport 1994; 5: 1929-1932.
33. Tonetto LL, Terzian AL, Del Bel EA, Guimaraes FS, Resstel LB. Inhibition of the NMDA receptor/nitric oxide pathway in the dorsolateral periaqueductal gray causes anxiolytic-like effects in rats submitted to the Vogel conflict test. Behav Brain Funct 2009; 5: 40.
34. Braga AA, Aguiar DC, Guimaraes FS. NOC-9, a selective nitric oxide donor, induces flight reactions in the dorsolateral periaqueductal gray of rats by activating soluble guanylate cyclase. Neurosci Lett 2009; 459: 79-83.
35. de Oliveira RW, Del Bel EA, Guimaraes FS. Behavioral and c-fos expression changes induced by nitric oxide donors microinjected into the dorsal periaqueductal gray. Brain Res Bull 2000; 51: 457-464.
36. Aguiar DC, Guimaraes FS. Blockade of NMDA receptors and nitric oxide synthesis in the dorsolateral periaqueductal gray attenuates behavioral and cellular responses of rats exposed to a live predator. J Neurosci Res 2009; 87: 2418-2429.
37. Beijamini V, Guimaraes FS. Activation of neurons containing the enzyme nitric oxide synthase following exposure to an elevated plus maze. Brain Res Bull 2006; 69: 347-355.
38. Beijamini V, Guimaraes FS. c-Fos expression increase in NADPH-diaphorase positive neurons after exposure to a live cat. Behav Brain Res 2006; 170: 52-61.
39. Bonassoli VT, Milani H, de Oliveira RM. Ethanol withdrawal activates nitric oxide-producing neurons in anxiety-related brain areas. Alcohol 2011; 45: 641-652.
40. Chiavegatto S, Scavone C, Canteras NS. Nitric oxide synthase activity in the dorsal periaqueductal gray of rats expressing innate fear responses. Neuroreport 1998; 9: 571-576.
41. Hall CW, Behbehani MM. Synaptic effects of nitric oxide on enkephalinergic, GABAergic, and glutamatergic networks of the rat periaqueductal gray. Brain Res 1998; 805: 69-87.
42. Moreira FA, Molchanov ML, Guimaraes FS. Ionotropic glutamate-receptor antagonists inhibit the aversive effects of nitric oxide donor injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 2004; 171: 199-203.
43. Miguel TT, Nunes-de-Souza RL. Defensive-like behaviors and antinociception induced by NMDA injection into the periaqueductal gray of mice depend on nitric oxide synthesis. Brain Res 2006; 1076: 42-48.
44. Miguel TT, Nunes-de-Souza RL. Anxiogenic-like effects induced by NMDA receptor activation are prevented by inhibition of neuronal nitric oxide synthase in the periaqueductal gray in mice. Brain Res 2008; 1240: 39-46.
45. Moreira FA, Guimaraes FS. Role of serotonin receptors in panic-like behavior induced by nitric oxide in the rat dorsolateral periaqueductal gray: effects of chronic clomipramine treatment. Life Sci 2005; 77: 1972-1982.
46. Miguel TL, Pobbe RL, Spiacci Junior A, Zangrossi Junior H. Dorsal raphe nucleus regulation of a panic-like defensive behavior evoked by chemical stimulation of the rat dorsal periaqueductal gray matter. Behav Brain Res 2010; 213: 195-200.
47. Moreira FA, Guimaraes FS. Benzodiazepine receptor and serotonin 2A receptor modulate the aversive-like effects of nitric oxide in the dorsolateral periaqueductal gray of rats. Psychopharmacology 2004; 176: 362-368.
48. Xing J, Li DP, Li J. Role of GABA receptors in nitric oxide inhibition of dorsolateral periaqueductal gray neurons. Neuropharmacology 2008; 54: 734-744.
49. Calixto AV, Duarte FS, Moraes CK, Faria MS, De Lima TC. Nitric oxide involvement and neural substrates of the conditioned and innate fear as evaluated in the T-maze test in rats. Behav Brain Res 2008; 189: 341-349.
50. de-Oliveira RW, Guimaraes FS. Anxiolytic effect of methylene blue microinjected into the dorsal periaqueductal gray matter. Braz J Med Biol Res 1999; 32: 1529-1532.
51. Carvalho-Netto EF, Gomes KS, Amaral VC, Nunes-deSouza RL. Role of glutamate NMDA receptors and nitric oxide located within the periaqueductal gray on defensive behaviors in mice confronted by predator. Psychopharmacology 2009; 204: 617-625.
52. Morato GS, Ortiga RM, Ferreira VM. Involvement of nitric oxide-dependent pathways of dorsolateral periaqueductal gray in the effects of ethanol in rats submitted to the elevated plus-maze test. Behav Brain Res 2004; 153: 341-349.
53. Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB, et al. Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plast 2009; 2009: 625-469.
54. Egertova M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 2003; 119: 481-496.
55. McGregor IS, Arnold JC, Weber MF, Topple AN, Hunt GE. A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrain. Brain Res 1998; 802: 19-26.
56. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-1112.
57. Finn DP, Jhaveri MD, Beckett SR, Kendall DA, Marsden CA, Chapman V. Cannabinoids modulate ultrasound-induced aversive responses in rats. Psychopharmacology 2004; 172: 41-51.
58. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA, et al. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 2003; 45: 594-604.
59. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 2007; 52: 958-965.
60. Lisboa SF, Resstel LB, Aguiar DC, Guimaraes FS. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 2008; 593: 73-78.
61. Resstel LB, Lisboa SF, Aguiar DC, Correa FM, Guimaraes FS. Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology 2008; 198: 405-411.
62. Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 2009; 8: 685-698.
63. Casarotto PC, Terzian AL, Aguiar DC, Zangrossi H, Guimaraes FS, Wotjak CT, et al. Opposing roles for cannabinoid receptor type-1 (CB(1)) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats. Neuropsychopharmacology 2012; 37: 478-486.
64. Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000; 57: 288-295.
65. Palazzo E, de Novellis V, Marabese I, Cuomo D, Rossi F, Berrino L, et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur J Pharmacol 2002; 439: 69-75.
66. Dean C. Cannabinoid and GABA modulation of sympathetic nerve activity and blood pressure in the dorsal periaqueductal gray of the rat. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1765-R1772.
67. Campos AC, Guimaraes FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 2008; 199: 223-230.
68. Campos AC, Guimaraes FS. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1517-1521.
69. Terzian AL, Aguiar DC, Guimaraes FS, Moreira FA. Modulation of anxiety-like behaviour by transient receptor potential vanilloid type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 2009; 19: 188-195.
70. Moreira FA, Aguiar DC, Terzian AL, Guimaraes FS, Wotjak CT. Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 2011; [http://dx.doi.org/10.1016/j.neuroscience.2011.08.046].
71. Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006; 139: 1405-1415.
72. Xing J, Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 2007; 97: 503-511.
73. Puente N, Cui Y, Lassalle O, Lafourcade M, Georges F, Venance L, et al. Polymodal activation of the endocannabinoid system in the extended amygdala. Nat Neurosci 2011; 14: 1542-1547.
74. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51: 159-212.
75. Carney ST, Lloyd ML, MacKinnon SE, Newton DC, Jones JD, Howlett AC, et al. Cannabinoid regulation of nitric oxide synthase I (nNOS) in neuronal cells. J Neuroimmune Pharmacol 2009; 4: 338-349.
76. Jones JD, Carney ST, Vrana KE, Norford DC, Howlett AC. Cannabinoid receptor-mediated translocation of NOsensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. Neuropharmacology 2008; 54: 23-30.
77. Maccarrone M, Fiori A, Bari M, Granata F, Gasperi V, De Stefano ME, et al. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 2006; 95: 117-127.
78. Thors L, Fowler CJ. Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids. Eur J Pharmacol 2009; 621: 10-18.
79. Stefano GB, Salzet B, Rialas CM, Pope M, Kustka A, Neenan K, et al. Morphineand anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res 1997; 763: 63-68.
80. Spina E, Trovati A, Parolaro D, Giagnoni G. A role of nitric oxide in WIN 55,212-2 tolerance in mice. Eur J Pharmacol 1998; 343: 157-163.
81. Azad SC, Marsicano G, Eberlein I, Putzke J, Zieglgansberger W, Spanagel R, et al. Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse. Eur J Neurosci 2001; 13: 561-568.
82. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999; 288: 1357-1366.
83. Rawls SM, Tallarida RJ, Gray AM, Geller EB, Adler MW. L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4 (4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6 H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J Pharmacol Exp Ther 2004; 308: 780-786.
84. Hillard CJ, Muthian S, Kearn CS. Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 1999; 459: 277-281.
85. Kim SH, Won SJ, Mao XO, Ledent C, Jin K, Greenberg DA. Role for neuronal nitric-oxide synthase in cannabinoidinduced neurogenesis. J Pharmacol Exp Ther 2006; 319: 150-154.
86. Lisboa S, Magesto AC, Resstel LB, Guimarães FS. Functional interaction between anadamide and neuronal nitric oxide synthase in the dorsolateral periaqueductal grey of rats induces complex modulation of anxiety-like behavior. Neuroscience Meeting 2011. Washington: 2011. p 123. (Abstract).
87. Cella M, Leguizamon GF, Sordelli MS, Cervini M, Guadagnoli T, Ribeiro ML, et al. Dual effect of anandamide on rat placenta nitric oxide synthesis. Placenta 2008; 29: 699-707.
88. Ching LC, Kou YR, Shyue SK, Su KH, Wei J, Cheng LC, et al. Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. Cardiovasc Res 2011; 91: 492-501.
89. Zschenderlein C, Gebhardt C, von Bohlen Und Halbach O, Kulisch C, Albrecht D. Capsaicin-induced changes in LTP in the lateral amygdala are mediated by TRPV1. PLoS One 2011; 6: e16116.